Jubilant Pharmova Limited
JUBLPHARMA · General/Diversified · NSE
₹964
Current Market Price
Fair Value (DCF)
₹718
Discount to FV
-25.6%
Updated just now
YieldIQ Score
46/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
40%
ROE
5.6%
Debt/Equity
0.51
WACC
9.9%
Market Cap
₹15,276 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.8%
Return on capital employed
EV / EBITDA
12.1×
Enterprise multiple
Debt / EBITDA
2.3×
Leverage vs earnings
Interest Coverage
5.4×
EBIT covers interest
Current Ratio
1.65×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
5.1%
3-year revenue growth
Revenue CAGR (5Y)
5.0%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹964.45
Bear case
Discount -143.7%
Base case
Discount -34.3%
Bull case
Discount +4.1%
Ratio Trends
JUBLPHARMA · last 9 annual periods
ROE
5.6%
ROCE
11.8%
Operating Margin
—
Debt / Equity
0.51×
PE
32.5×
EV / EBITDA
12.1×
Historical Financials
JUBLPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹6059 Cr | ₹6219 Cr | ₹6645 Cr | ₹7192 Cr | ₹8225 Cr | +7.9% |
| EBITDA | ₹1150 Cr | ₹750 Cr | ₹809 Cr | ₹1590 Cr | ₹1266 Cr | +2.4% |
| EBIT | ₹786 Cr | ₹204 Cr | ₹419 Cr | — | — | -14.6% |
| PAT | ₹414 Cr | ₹-61.0 Cr | ₹77.1 Cr | ₹839 Cr | ₹399 Cr | -0.9% |
| EPS (diluted) | ₹26.00 | ₹-3.83 | ₹4.86 | — | — | -34.2% |
| CFO | ₹838 Cr | ₹661 Cr | ₹971 Cr | ₹1072 Cr | ₹1227 Cr | +10.0% |
| CapEx | ₹-600 Cr | ₹-815 Cr | ₹-898 Cr | ₹-1116 Cr | ₹-1449 Cr | — |
| FCF | ₹238 Cr | ₹-154 Cr | ₹73.6 Cr | ₹-43.5 Cr | ₹-222 Cr | — |
| Total Assets | ₹9991 Cr | ₹11.2K Cr | ₹11.5K Cr | ₹12.8K Cr | ₹15.5K Cr | +11.6% |
| Total Debt | ₹3192 Cr | ₹3677 Cr | ₹3664 Cr | ₹2731 Cr | ₹3615 Cr | +3.2% |
| Shareholders' Equity | ₹5319 Cr | ₹5399 Cr | ₹5434 Cr | ₹6255 Cr | ₹7093 Cr | +7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JUBLPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 COHANCE COHANCE | — | — | Pending | 4.6% | — |
 APLLTD APLLTD | — | — | Pending | 11.9% | 19.3× |
 CAPLIPOINT CAPLIPOINT | — | — | Pending | 17.9% | 17.8× |
ALIVUS ALIVUS | — | — | Pending | 16.9% | — |
 GRANULES GRANULES | — | — | Pending | 11.7% | 25.8× |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹25.00/sh
Last payout
2025-07-25
₹5.00
Peak payout
₹5.00
Trailing yield
0.52%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Jubilant Pharmova Limited (JUBLPHARMA.NS) trades at 964.45 vs a model fair value of 717.88, a gap of -25.6%. Piotroski F-score: 6/9. Moat...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JUBLPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JUBLPHARMA →
Compare
Head-to-head with peers
Compare JUBLPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JUBLPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.